Revolutionizing Healthcare: Wolters Kluwer's Acquisition of Invistics Flowlytics Diversion Software

Our Guest: Karen KobelskiVice President & General Manager at Wolters KluwerIn this episode, we sit down with Karen Kobelski, the VP and General Manager of Wolters Kluwer, to delve into the innovative healthcare products offered by WK and their recent strategic acquisition of Invistics Flowlytics diversion software. Wolters Kluwer is renowned for providing clinical technology and evidence-based solutions that enhance decision-making and outcomes across the healthcare spectrum.We explore the rationale behind WK's decision to integrate diversion detection software into their portfolio, emphasizing the importance of safeguarding healthcare environments from drug diversion. Karen shares insights into why Invistics Flowlytics stood out among various options and the strategic alignment with WK's mission.Tune in to learn about the future goals for Sentri7 Diversion (formerly known as Flowlytics) and how this powerful tool is poised to revolutionize diversion detection and bolster the integrity of healthcare operations